Valuation check: PRQR's profit margin is -228.38%, below the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
ProQR Therapeutics N.V (PRQR) currently reports a profit margin of -228.38% as of June 2026. That compares with -240.63% in the prior-year period — up 5.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore ProQR Therapeutics N.V's profit margin history and peer comparisons.
ProQR Therapeutics N.V's profit margin increased from -240.63% to -228.38% — a 5.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
ProQR Therapeutics N.V's profit margin of -228.38% is lower than the Healthcare sector average of 13.89%. That is roughly 1744.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but ProQR Therapeutics N.V's current -228.38% should be judged against Healthcare norms (sector average: 13.89%) and against PRQR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -228.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for ProQR Therapeutics N.V, and consider following PRQR for alerts when major investors trade the stock.